GLOBOCAN 2012. Cancer incidence and mortality worldwide: IARC CancerBase No. 11 database (http://globocan.iarc.fr). International Agency for Research on Cancer; 2013. Accessed 14 March 2014.
Loeb, S, et al.
Systematic review of complications of prostate biopsy. European Urology
2013; 64: 876–892.
Djavan, B, et al.
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. Journal of Urology
2001; 166: 856–860.
Roberts, MJ, et al.
Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: a bias-adjusted meta-analysis. International Journal of Antimicrobial Agents
2014; 43: 301–309.
Williamson, DA, et al.
Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli
. Clinical Infectious Diseases
2013; 57: 267–274.
Williamson, DA, et al.
Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clinical Infectious Diseases
2012; 54: 1406–1412.
Carignan, A, et al.
Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?
2012; 62: 453–459.
Nam, RK, et al.
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. Journal of Urology
2013; 189: S12–S17.
Steensels, D, et al.
Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy – should we reassess our practices for antibiotic prophylaxis?
Clinical Microbiology and Infection
2012; 18: 575–581.
Simsir, A, et al.
Is it possible to predict sepsis, the most serious complication in prostate biopsy?
2010; 84: 395–399.
Liss, MA, et al.
Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. Journal of Urology
2011; 185: 1283–1288.
Zowawi, HM, et al.
The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nature Reviews Urology
2015; 12: 570–584.
Takenaka, A, et al.
A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer and Prostatic Diseases
2008; 11: 134–138.
Hossack, T, et al.
Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy. Journal of Urology
2012; 188: 781–785.
Shen, PF, et al.
The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis. Asian Journal of Andrology
2012; 14: 310–315.
Hara, R, et al.
Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology
2008; 71: 191–195.
Miller, J, Perumalla, C, Heap, G. Complications of transrectal versus transperineal prostate biopsy. Australia and New Zealand Journal of Surgery
2005; 75: 48–50.
Dimmen, M, et al.
Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies. BJU International
2012; 110: E69–75.
Nesi, MH, et al.
A comparison of morbidity following transrectal and transperineal prostatic needle biopsy. Surgery, Gynecology & Obstetrics
1983; 156: 464–466.
Higgins, JPT, Green, S (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 (www.cochrane-handbook.org).
Moher, D, et al.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology
2009; 62: 1006–1012.
Hoy, D, et al.
Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. Journal of Clinical Epidemiology
2012; 65: 934–939.
Bennett, H, et al.
Major complications following prostate biopsy: a meta-analysis of the international literature. BJU International
2014; 113: 32–33.
Doi, SA, et al.
Simulation comparison of the quality effects and random effects methods of meta-analysis. Epidemiology. 2015; 26: E42–44.
Doi, SA, et al.
Advances in the meta-analysis of heterogeneous clinical trials I: the inverse variance heterogeneity model. Contemporary Clinical Trials
2015; 45: 130–138.
Doi, SAR, Barendregt, JJ, Rao, C. An updated method for risk adjustment in outcomes research. Value in Health
2014; 17: 629–633.
Barendregt, JJ, et al.
Meta-analysis of prevalence. Journal of Epidemiology and Community Health
2013; 67: 974–978.
Onitilo, AA, Doi, SAR, Barendregt, J.J
Meta-analysis II. In: Doi SAR, Williams, GM, eds. Methods of Clinical Epidemiology. Springer Series on Epidemiology and Public Health. Berlin Heidelberg: Springer, 2013, pp. 253–266.
Hunter, JP, et al.
In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. Journal of Clinical Epidemiology
2014; 67: 897–903.
Thompson, PM, et al.
The problem of infection after prostatic biopsy: the case for the transperineal approach. BJU. 1982; 6: 736–740.
Batura, D, Rao, GG. The national burden of infections after prostate biopsy in England and Wales: A wake-up call for better prevention. Journal of Antimicrobial Chemotherapy
2013; 68: 247–249.
Kapoor, DA, et al.
Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology
1998; 52: 552–558.
Johnson, L, et al.
Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. American Journal of Medicine
2008; 121: 876–884.
Apisarnthanarak, A, et al.
Nonjudicious dispensing of antibiotics by drug stores in Pratumthani, Thailand. Infection Control and Hospital Epidemiology
2008; 29: 572–575.
Williamson, DA, et al.
Travel-associated extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infection following transrectal ultrasound-guided prostate biopsy. BJU International
2012; 109: E21–22.
Feliciano, J, et al.
The incidence of fluoroquinolone resistant infections after prostate biopsy – are fluoroquinolones still effective prophylaxis?
Journal of Urology
2008; 179: 952–955.
Taylor, S, et al.
Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU International
2013; 111: 946–953.